Contact Us
Filling this form is the simpliest way to contact us by email.
If you wish to visit us, please click here for full maps and details.
© 2002 Immutep, S.A.
On this page: |
Contact UsFilling this form is the simpliest way to contact us by email. If you wish to visit us, please click here for full maps and details. © 2002 Immutep, S.A.
|
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer. 05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial 01/2010 - Interview Frederic Triebel with PharmaTelevision 01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer |
|||||||||||||||||||